Transcatheter Technologies will report one-year follow-up results for study of its ‘truly repositionable’ Trinity TAVI system at ‘TCT 2014’ in Washington, DC

“Speaking as a physician who has used various TAVI systems and has experienced their flaws, I therefore know firsthand why our third-generation Trinity system could be a game-changer for TAVI.” Wolfgang Goetz, MD, CEO

REGENSBURG, Germany — Transcatheter Technologies GmbH, an emerging medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system—Trinity—will disclose the successful one-year follow-up results of its Trinity TAVI system that is designed to be the world’s first ‘truly repositionable’ and best TAVI system.
 
The clinical data will be presented during ‘TCT 2014’ on Monday, Sept. 15, 4:25 p.m. ET, at the Walter E. Washington Convention Center, Level 2, Room 202A/B, “Early Stage New TAVR Systems: Trinity Valve – Technology Review, Clinical Results, and Case Examples.”
 
“The one-year follow-up clinical results are impressive,” said principal investigator Prof. Dr. Christian Hengstenberg, a cardiologist at the German Heart Center, Munich, Germany, who will present the Trinity data at TCT 2014. “Unlike currently marketed TAVI systems, the Trinity aortic valve can be positioned precisely or even repositioned after full implantation in a safe manner. Equally important, Trinity’s unique sealing cuff continues to provide outstanding results without PVL, a well-known and frequent complication of TAVI. Furthermore, the risk of atrio-ventricular (AV) block has been essentially alleviated because of the supra-annular positioning of the Trinity valve.”
 
“An unforgiving limitation of currently marketed TAVI systems is that they can not be repositioned once fully implanted. Conversely, Trinity is designed to correct this life-threatening imperfection and therein abate the unwelcome side effects of PVL and AV block,” said Wolfgang Goetz, M.D., Ph.D., CEO, a cardiac surgeon who has used many of the currently marketed TAVI systems. “The huge advantage of Trinity is that once the valve is completely expanded and anchored above the annulus, you are then able to entirely evaluate the valve’s function, unlike currently marketed TAVI systems, to decide if it needs to be repositioned, retrieved, or kept in the same position. This feature is absolutely unique to Trinity and the reason why we have positioned Trinity as the Third-Generation TAVI System.”

Source: Transcatheter Technologies GmbH